chufangao/CTO huggingface dataset:
Clinical trial NCT03393962: Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Official title: Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)
Sponsor: Shenzhen Geno-Immune Medical Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: combine with another trial
Enrollment: 20.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2017-12-01
Primary completion date: 2020-01-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT04984798: Vitamin E Efficacy in HI/HA
Official title: Efficacy of Vitamin E in Hyperinsulinism/Hyperammonemia Syndrome
Sponsor: Children's Hospital of Philadelphia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No study activity took place. The IND was withdrawn with the FDA by the Sponsor Investigator because of insurmountable hurdles in moving proposed research forward
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-11-30
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT05420077: Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273
Official title: Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of RVM-V001 in Healthy Individuals Aged 18-65 Years Previously Vaccinated With BNT162b2 and mRNA-1273
Sponsor: RVAC Medicines (US), Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The landscape of the study area changed, making it impossible to continue the study.
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-12
Primary completion date: 2023-06-02
Completion date: 2023-06-02
Clinical trial NCT02414750: Vemurafenib Plus Cobimetinib in Metastatic Melanoma
Official title: A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics
Acronym: REPOSIT
Sponsor: Netherlands Working Group on Immunotherapy of Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual and changing treatment landscape
Enrollment: 78.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-12-31
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03110380: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed
Official title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects Who Are Virologically Suppressed
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 567.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-06-12
Primary completion date: 2018-12-04
Completion date: 2021-02-10
Baseline population: The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
IPD time frame: 18 months after study completion
IPD access criteria: A secured external environment with username, password, and RSA code.
Clinical trial NCT04530149: Vital Capacity in Ultrasound Guided Serratus Plane Block in ED Patients With Multiple Rib Fractures
Official title: Vital Capacity in Ultrasound Guided Serratus Plane Block in Emergency Department Patients With Multiple Rib Fractures: A Randomized Controlled Trial
Sponsor: Maimonides Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The original PI left the institution; COVID interrupted the study; difficult enrolling patients.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-01
Primary completion date: 2024-03-04
Completion date: 2024-03-04
Plan to share individual participant data: NO
Clinical trial NCT05715125: VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients With Active Psoriatic Arthritis
Sponsor: Ventyx Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: sponsor decision
Enrollment: 205.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-01-31
Primary completion date: 2024-01-02
Completion date: 2024-01-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04110054: Evaluation of S-600918 in Adults With Refractory Chronic Cough
Official title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-selection Study of S-600918 in Patients With Refractory Chronic Cough
Sponsor: Shionogi Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 406.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-02-13
Primary completion date: 2020-12-08
Completion date: 2020-12-28
Baseline population: Full Analysis Set included all randomized participants who received at least 1 dose of study drug and who had cough monitor assessment at both baseline and at least 1 visit after initiation of study drug administration.
Clinical trial NCT04808362: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
Official title: A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the MYC Inhibitor OMO-103 Administered Intravenously in Patients With Advanced Solid Tumours
Acronym: MYCure
Sponsor: Peptomyc S.L. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Phase 1completed; sponsor decided to change strategy to a combination study
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-28
Primary completion date: 2022-12-15
Completion date: 2023-01-11
Plan to share individual participant data: NO
Clinical trial NCT04386980: Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed
Official title: A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: To be replaced by a different protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT04251169: Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression
Official title: Targeting Non-Luminal Disease by PAM50 With Pembrolizumab + Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced/Metastatic Breast Cancer, Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
Acronym: TATEN
Sponsor: SOLTI Breast Cancer Research Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The enrollment was stopped prematurely due to the lack of funding
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-21
Primary completion date: 2024-04-10
Completion date: 2024-04-30
Clinical trial NCT04532749: A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Official title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: 42847922MDD3002 was stopped based on the interim analysis (IA) results as recommended by the Independent Data Monitoring Committee (IDMC)
Enrollment: 212.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-15
Primary completion date: 2022-05-24
Completion date: 2022-07-14
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Clinical trial NCT04638400: Anti-inflammatory Effects of Simvastatin
Official title: Comparison of Effects of Simvastatin Versus Ezetimibe on Intracellular Lipid and Inflammation in Obese Subjects
Sponsor: State University of New York at Buffalo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of recruitment- Fellow responsible for study graduated
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-01
Primary completion date: 2021-08-01
Completion date: 2021-11-01
Clinical trial NCT04346394: The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease
Official title: The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease: Orthostatic Hypotension and Other Nonmotor Symptoms
Acronym: NAinPD
Sponsor: Dartmouth-Hitchcock Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: COVID-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-11
Primary completion date: 2023-08-01
Completion date: 2023-08-01
Clinical trial NCT04705597: Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19
Sponsor: BioAge Labs, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The incidence of COVID-19 hospitalization cases decreased to a level that continued enrollment was no longer feasible
Enrollment: 194.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-18
Primary completion date: 2022-04-20
Completion date: 2022-05-19
Baseline population: The Intent-to-Treat (ITT) Analysis Set includes all randomized participants and was used for baseline characteristics
Plan to share individual participant data: NO
Clinical trial NCT03085810: Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
Official title: An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1239.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-24
Primary completion date: 2023-04-27
Completion date: 2023-04-27
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02588807: Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis
Official title: The Combination of Phospholipids and Medical Herbs for the Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS); A Pilot Study
Acronym: ALS-PHL
Sponsor: Herb Spirit (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The sponsor and hospital did not reach agreement
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-01
Primary completion date: 2021-09-30
Completion date: 2022-05-31
Clinical trial NCT04338022: Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
Official title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 1)
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.
Enrollment: 1124.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-12
Primary completion date: 2023-10-02
Completion date: 2024-03-08
Plan to share individual participant data: YES
IPD sharing description: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
IPD time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union
IPD access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.
Clinical trial NCT04337749: Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination for Prevention of Pitted Keratolysis
Official title: A Study of Efficacy of Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination of Chlorhexidine Scrub and ZnO Nanoparticles Socks for Prevention of Pitted Keratolysis
Acronym: PKprevention
Sponsor: Mahidol University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: After discussing within the team, the project has been withdrawn due to the anticipated insufficiency of sample size.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-11-05
Primary completion date: 2022-12-01
Completion date: 2022-12-01
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available.
Clinical trial NCT03281681: A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Official title: A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Acronym: REPROVe
Sponsor: Kintara Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Alternate study design for ovarian cancer under discussion
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-31
Primary completion date: 2022-03-31
Completion date: 2022-09-30
Plan to share individual participant data: NO
IPD sharing description: The Clinical Study Report for this trial will be prepared and provided to the U.S. FDA as required by applicable regulatory requirement(s). Each participating trial investigator will be provided a copy of their patient data captured in the database for this trial.
Clinical trial NCT02097225: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Official title: Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Drug supply issues
Enrollment: 22.0 (ACTUAL)
Number of arms: 5.0
Start date: 2014-05-29
Primary completion date: 2019-03-31
Completion date: 2022-10-26
Baseline population: No participants were enrolled into fallback Dose Level -1 because Dose Level -1 is only initiated if more than 1 of 6 subjects in dose level 1 (starting dose) develop DLTs.
Clinical trial NCT04238663: Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers
Official title: A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin® and EU Approved Avastin® in Healthy Male Volunteers
Sponsor: mAbxience Research S.L. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 115.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-24
Primary completion date: 2020-03-17
Completion date: 2020-03-17
Clinical trial NCT02448420: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer
Official title: A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
Acronym: PATRICIA II
Sponsor: SOLTI Breast Cancer Research Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 73.0 (ACTUAL)
Number of arms: 5.0
Start date: 2015-07-31
Primary completion date: 2023-09-29
Completion date: 2023-11-30
Clinical trial NCT04101357: Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
Official title: Phase 1/2a, First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT411 as a Monotherapy in Patients With Solid Tumors and in Combination With Atezolizumab, Carboplatin and Etoposide in Patients With Chemotherapy-naïve Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sponsor: BioNTech SE (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 55.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-19
Primary completion date: 2024-01-19
Completion date: 2024-05-23
Plan to share individual participant data: NO
Clinical trial NCT04276597: Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Official title: A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
Acronym: PUTNET
Sponsor: Excel Diagnostics and Nuclear Oncology Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No subjects were eligible for the study. The study closed on 07-15-2021.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-04
Primary completion date: 2021-07-15
Completion date: 2021-07-15
Plan to share individual participant data: NO
Clinical trial NCT02985554: Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Official title: Phase I Study to Assess the Tolerability and Efficacy of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study stopped early due to slow accrual and safety concerns.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-20
Primary completion date: 2019-02-06
Completion date: 2020-06-22
Clinical trial NCT03988114: A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
Official title: A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Acronym: proMONARCH
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Strategic decision due to emerging new data for patients with HR+, HER2- metastatic breast cancer.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-16
Primary completion date: 2022-03-23
Completion date: 2023-03-23
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT02564536: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
Official title: A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Lack of funding following full FDA clinical hold
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT04541550: Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa
Official title: An Open-label, Dose-escalation Study to Evaluate the Use of Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa
Sponsor: IntegoGen, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study didn't proceed to FDA submission
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-04-01
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Plan to share individual participant data: NO